177 results match your criteria infusions itp


Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

Blood Adv 2020 09;4(17):4136-4146

Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom.

Primary immune thrombocytopenia (ITP) is a predominantly immunoglobulin G (IgG)-autoantibody-mediated disease characterized by isolated thrombocytopenia. Rozanolixizumab, a subcutaneously infused humanized monoclonal anti-neonatal Fc receptor (FcRn) antibody, reduced serum IgG in healthy volunteers. In this phase 2, multicenter, open-label study, patients with persistent/chronic primary ITP received 1 to 5 once-weekly subcutaneous infusions of rozanolixizumab (cumulative doses, 15-21 mg/kg). Read More

View Article and Full-Text PDF
September 2020

Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial.

Haematologica 2020 08 13. Epub 2020 Aug 13.

Centre Hospitalier Universitaire Henri-Mondor, Université Paris Est Creteil, Creteil, France.

B-cell activating factor may be involved in the failure of B-cell depleting therapy with rituximab in immune thrombocytopenia (ITP) by promoting the emergence of splenic long-lived plasma cells. From results obtained in mouse models, we hypothesized that combining rituximab with sequential injections of belimumab could increase the rate of response at one year in patients with persistent or chronic ITP by preventing the emergence of these long-lived plasma cells. The study was a single-center, single arm, prospective phase 2b trial (RITUX-PLUS, NCT03154385) investigating the safety and efficacy of rituximab given at a fixed dose of 1,000 mg, two weeks apart, combined with five infusions of belimumab, 10 mg/kg at week 0 (W0)+2 days, W2+2 days, W4, W8 and W12 for adults with primary persistent or chronic ITP. Read More

View Article and Full-Text PDF

Rituximab and immune thrombocytopenia in adults: The state of knowledge 20 years later.

Rev Med Interne 2021 Jan 14;42(1):32-37. Epub 2020 Jul 14.

Service de Médecine Interne, Centre de Référence des Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France. Electronic address:

Rituximab has been used for immune thrombocytopenia (ITP) for almost 20 years and is now considered a valid off-label second-line treatment. About 60% to 70% of patients with ITP show initial response to rituximab, but in half of these patients, the disease will eventually relapse. Therefore, in 30% of patients with persistent or chronic ITP, one course of rituximab at 375 mg/m/week for 4 weeks or 2 fixed 1000-mg rituximab infusions allows for a sustained response rate at 5 years. Read More

View Article and Full-Text PDF
January 2021

Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura.

Intern Med 2020 Apr 20;59(7):983-986. Epub 2019 Dec 20.

Department of Nephrology, Kurashiki Central Hospital, Japan.

A 22-year-old woman had been diagnosed with idiopathic thrombocytopenic purpura (ITP) 5 years earlier. After undergoing splenectomy, she relapsed frequently following prednisolone tapering. She was complicated with minimal change nephrotic syndrome (MCNS) while taking 20 mg of prednisolone. Read More

View Article and Full-Text PDF

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.

Am J Hematol 2020 02 10;95(2):178-187. Epub 2019 Dec 10.

Department of Hematology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, characterized by a low platelet count (<100 × 10 /L) in the absence of other causes associated with thrombocytopenia. In most patients, IgG autoantibodies directed against platelet receptors can be detected. They accelerate platelet clearance and destruction, inhibit platelet production, and impair platelet function, resulting in increased risk of bleeding and impaired quality of life. Read More

View Article and Full-Text PDF
February 2020

Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.

Am J Hematol 2019 12 8;94(12):1314-1324. Epub 2019 Oct 8.

Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France.

Rituximab is a second-line option in adults with immune thrombocytopenia (ITP), but the estimated 5-year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long-term safety. We conducted a prospective multicenter registry of 248 adults with ITP treated with rituximab with 5 years of follow-up to assess its long-term safety and efficacy. The median follow-up was 68. Read More

View Article and Full-Text PDF
December 2019

Appropriateness of intravenous immunoglobulin use in immune thrombocytopenia (ITP): A Canadian centre deep dive audit.

Transfus Apher Sci 2019 Aug 10;58(4):491-494. Epub 2019 May 10.

Division of Adult and Pediatric Hematology, University of Toronto, 190 Elizabeth Street, R. Fraser Elliott Building, 3-805, Toronto, ON, M5G, Canada; Departments of Medicine and Laboratory Medicine, St. Michael's Hospital, 30 Bond St., Toronto, ON, M5B 1W8, Canada; Li Ka Shing Knowledge Institute, 209 Victoria St, Toronto, ON, M5B 1T8, Canada. Electronic address:

Objectives: Assess the appropriateness of the use of intravenous immunoglobulin (IVIG) for immune thrombocytopenia (ITP).

Background: IVIG is suggested for ITP when a rapid increase in platelet count is desired or as first line therapy if corticosteroids are contraindicated. A recent Canadian audit of IVIG requests found a lack of compliance with provincial requirements and inadequate documentation of efficacy which led the authors to conclude that the use of IVIG was broadly inappropriate for all treated diseases. Read More

View Article and Full-Text PDF

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia.

J Hematol 2018 Sep 1;7(3):87-95. Epub 2018 Sep 1.

Institute for Transfusion Medicine, Charite Campus Virchow-Klinikum, Berlin, Germany.

Background: Intravenous immunoglobulin (IVIG) IQYMUNE® is a highly purified 10% IVIG that was assessed using the new stringent definition of response described in the revised guideline on the clinical investigation of IVIG. The efficacy and the safety of IQYMUNE® were investigated in adult patients with chronic primary immune thrombocytopenia (ITP).

Methods: In this phase III multinational, multicentre, prospective, uncontrolled, open-label, single-arm study, adult patients with a baseline platelet count < 30 × 10/L were treated with IVIG 10% at a dose of 2 g/kg body weight administered over 2 consecutive days. Read More

View Article and Full-Text PDF
September 2018

Long-term compliance with a validated intravenous insulin therapy protocol in cardiac surgery patients: a quality improvement project.

Int J Qual Health Care 2018 Dec;30(10):817-822

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, 3 bvd Alexander Fleming, Besancon, France.

Quality Problem: Safe and efficient blood glucose (BG) level control after cardiac surgery relies on an intensive care unit (ICU) team-based approach, including implementation of a dynamic insulin therapy protocol (ITP). Long-term compliance with such a complex protocol is poorly addressed in the literature. The aim of this study was to assess the long-term compliance of nurses with the ITP, 7 years after its implementation in the ICU. Read More

View Article and Full-Text PDF
December 2018

Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.

J Pediatr 2017 12;191:225-231

Division of Pediatric Hematology, Weill Cornell Medicine, New York, NY.

Objectives: To assess initial and long-term outcome of children with persistent/chronic idiopathic thrombocytopenic purpura (ITP) treated with 4 infusions of rituximab and three 4-day cycles of dexamethasone (4R+3Dex) including cohorts with most benefit and/or treatment associated toxicity.

Study Design: All pediatric patients with ITP at Weill-Cornell who received 4R+3Dex were included in this retrospective study. Duration was median time from first rituximab infusion to treatment failure. Read More

View Article and Full-Text PDF
December 2017

Tolerability and safety of the intravenous immunoglobulin octagam 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials.

Hematology 2018 May 11;23(4):242-247. Epub 2017 Oct 11.

c Octapharma Inc. , Hoboken , NJ , USA.

Objectives: To provide detailed data on the tolerability and safety of octagam 10%, a ready-to-use intravenous immunoglobulin, in a subgroup of patients with immune thrombocytopenia (ITP) involved in an integrated analysis of post-authorisation safety surveillance (PASS) studies.

Methods: A subgroup analysis was conducted using data collected from two non-interventional studies that included patients with ITP treated with octagam 10%. Patients were observed and monitored for possible adverse drug reactions (ADRs) during or after administration of octagam 10%, with a particular focus on thromboembolic events (TEEs). Read More

View Article and Full-Text PDF

Anterior ST-elevation myocardial infarction induced by rituximab infusion: A case report and review of the literature.

J Clin Pharm Ther 2017 Jun;42(3):356-362

Department of Medicine "B", Sheba Medical Center, Tel-Hashomer, Israel.

What Is Known And Objectives: Rituximab is a chimeric monoclonal anti-CD20 antibody approved for the treatment of some lymphoid malignancies as well as for autoimmune diseases including rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP) and vasculitis. Generally, rituximab is well tolerated; nevertheless, some patients develop adverse effects including infusion reactions. Albeit rare, these reactions may in some cases be life-threatening conditions. Read More

View Article and Full-Text PDF

Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.

Eur Ann Allergy Clin Immunol 2017 Jan;49(1):11-14

Kanuni Sultan Suleyman Research and Training Hospital, Department of Pediatric Allergy-Immunology, Istanbul, Turkey. E-mail:

Intravenous immunoglobulin (IVIG) is commonly used in primary and secondary immunodeficiency diseases as well as autoimmune conditions as immunomodulatator treatment. Immediate adverse events which are generally mild and occur during infusion are seen in 6 hours. Reported immediate adverse events are in a wide range from 1%-40% in pediatric patients. Read More

View Article and Full-Text PDF
January 2017

Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia.

Int Immunopharmacol 2017 Mar 7;44:38-42. Epub 2017 Jan 7.

Department of Molecular Medicine, "Sapienza" University of Rome, Italy.

Intravenous immunoglobulin (IVIg) is accepted as an effective and well-tolerated treatment for primary and secondary immunodeficiencies (ID) and immune thrombocytopenia (ITP). Adverse reactions of IVIg are usually mild, comprising transient flu-like symptoms, change in blood pressure and tachycardia. However IVIg therapy can be burdensome for both patients and healthcare facilities, since the infusion may take up to 4h to administer. Read More

View Article and Full-Text PDF

NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia.

Clin Immunol 2017 04 18;177:18-28. Epub 2015 Nov 18.

Centre d'Immunologie de Marseille-Luminy, Aix-Marseille University UM2, Inserm, U1104, CNRS UMR7280, 13288 Marseille, France; Immunologie, Hôpital de la Conception, Assistance Publique - Hôpitaux de Marseille, Aix-Marseille Université, 13005 Marseille, France. Electronic address:

Immune thrombocytopenic purpura (ITP) is a disease characterized by antibody-mediated platelet destruction. The T- and B-cell subsets have been extensively studied in primary ITP, but the NK cell compartment has been less thoroughly explored. We investigated the NK cell receptor repertoire and the functionality of NK cells in the peripheral blood and spleen in patients with primary ITP. Read More

View Article and Full-Text PDF

Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study.

Int J Hematol 2016 Feb 20;103(2):180-8. Epub 2015 Nov 20.

Department of Hematology-Oncology, Inha University College of Medicine and Hospital, 7-206 Third Street, Shinheung-dong Jung-gu, Incheon, Republic of Korea.

Therapeutic options for immune thrombocytopenia (ITP) patients after splenectomy failure are limited. In the present study, we evaluated the role of vincristine in patients who relapsed after or were refractory to splenectomy for ITP. Sixty-two ITP patients treated with vincristine after splenectomy were retrospectively analyzed. Read More

View Article and Full-Text PDF
February 2016

Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.

Transfusion 2016 Jan 24;56(1):73-9. Epub 2015 Sep 24.

Department of Medicine Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario.

Background: Thrombopoietin receptor agonists are new treatments for patients with chronic immune thrombocytopenia (ITP). How one of these agent, romiplostim, has impacted practice patterns, especially the use of intravenous immune globulin (IVIG), has not been evaluated outside of clinical trials.

Study Design And Methods: This was a retrospective cohort study of adult ITP patients treated with romiplostim in four Canadian centers. Read More

View Article and Full-Text PDF
January 2016

Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP.

Eur Rev Med Pharmacol Sci 2015 ;19(9):1583-8

Department of Hematology, Qing-dao Central Hospital, Qing-dao, China.

Objective: This work aims to observe the efficacy and safety of low-dose rituximab in combination with recombinant human thrombopoietin in treating immune thrombocytopenia (ITP).

Patients And Methods: Fourteen ITP patients were treated four times with 100 mg qw of rituximab in combination with 300 µg/kg/d ih recombinant human thrombopoietin (rhTPO) for 14 d. Platelet count in peripheral blood, serum immunoglobulin, and lymphocyte subgroups by flow cytometry were detected regularly both pre- and post-treatment. Read More

View Article and Full-Text PDF

Immune Thrombocytopenic Purpura During Maintenance Phase of Acute Lymphoblastic Leukemia: A Rare Coexistence Requiring a High Degree of Suspicion, a Case Report and Review of the Literature.

Turk J Haematol 2015 Dec 27;32(4):363-6. Epub 2015 Apr 27.

Hacettepe University Faculty of Medicine, Division of Pediatric Hematology, Ankara, Turkey Phone: +90 312 305 11 72 E-mail:

Thrombocytopenia may develop in patients with acute lymphoblastic leukemia (ALL) due to myelosuppression of chemotherapy or relapse. Here we report a pediatric patient with ALL whose platelet counts decreased at the 102nd week of maintenance treatment. Thrombocytopenia was refractory to platelet infusions and bone marrow aspiration revealed remission status for ALL along with increased megakaryocytes. Read More

View Article and Full-Text PDF
December 2015

Use of romiplostim in patients with chronic idiopathic thrombocytopenic purpura during perioperative period.

Intern Med J 2015 Jul;45(7):718-24

Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.

Introduction: In patients with chronic idiopathic thrombocytopenic purpura (cITP), the platelet count tends to be quite variable and, in the majority of cases, specific therapy is not warranted on a regular basis. However, patients with low platelet count (<30 nL) or with bleeding complications would require therapy, such as prednisolone, intravenous immunoglobulin infusions, splenectomy and/or immunosuppression. Romiplostim, a thrombopoietin agonist, has also proven to be useful in improving platelet counts. Read More

View Article and Full-Text PDF

Intravenous Immunoglobulin (IVIg) Utilization in Immune Thrombocytopenia (ITP): A Multi-Center, Retrospective Review.

Drugs Real World Outcomes 2015 Mar;2(1):35-42

Department of Medicine, McMaster University, Hamilton, ON, Canada.

Introduction: Intravenous immunoglobulin (IVIg) is an immune thrombocytopenia (ITP) therapy, which is associated with toxicities, limited availability, increasing utilization, and high cost. This study aimed to assess short- and long-term IVIg utilization in patients with ITP at two tertiary care centers in Ontario, Canada, to determine the proportion of IVIg used in ITP compared with all usage, and to forecast IVIg demand in ITP.

Methods: Records from all adult ITP patients who received IVIg between January 1, 2003, and September 30, 2012, at Hamilton Health Sciences and London Health Sciences Centre were reviewed retrospectively. Read More

View Article and Full-Text PDF

Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.

Blood 2014 Nov 7;124(22):3228-36. Epub 2014 Oct 7.

Service de Médecine Interne, Centre de Référence Labellisé des Cytopénies Auto-Immunes de l'Adulte and.

We conducted a prospective multicenter registry of 248 adult patients with immune thrombocytopenia (ITP) treated with rituximab to assess safety. We also assessed response and predictive factors of sustained response. In total, 173 patients received 4 infusions of 375 mg/m(2) and 72 received 2 fixed 1-g infusions 2 weeks apart. Read More

View Article and Full-Text PDF
November 2014

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.

Haematologica 2014 Jul 18;99(7):1264-71. Epub 2014 Apr 18.

Departments of Pediatrics and Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA Department of Medicine, Østfold Hospital Trust, Fredrikstad, Norway.

Adults with newly diagnosed or persistent immunothrombocytopenia frequently relapse upon tapering steroids; adults and children with chronic disease have an even lower likelihood of lasting response. In adults with newly-diagnosed immunothrombocytopenia, two studies showed that dexamethasone 40 mg/day × four days and 4 rituximab infusions were superior to dexamethasone alone. Studies have also shown three cycles of dexamethasone are better than one and patients with persistent/chronic immunothrombocytopenia respond less well to either dexamethasone or rituximab. Read More

View Article and Full-Text PDF

Is B-cell depletion still a good strategy for treating immune thrombocytopenia?

Presse Med 2014 Apr 14;43(4 Pt 2):e79-85. Epub 2014 Mar 14.

St George's Hospital, Haematology SpR, Blackshaw Road, Tooting, London SW17 0QT, UK.

B cells play an important role in the pathophysiology of immune thrombocytopenia (ITP). Thus, a rational approach to ITP treatment involves B-cell depletion such as with rituximab. More than 10 years after the first reports of data suggesting that anti-CD20 MoAbs could be effective treatment for ITP, we have now a clear view of its efficacy, with an overall response in about 60% of patients. Read More

View Article and Full-Text PDF

[Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].

Med Clin (Barc) 2015 May 22;144(9):389-96. Epub 2014 Feb 22.

Global Health Economics, Amgen (Europe) GmbH, Zug, Suiza. Electronic address:

Background And Objective: Romiplostim, a thrombopoietin-receptor agonist, is approved for second-line use in idiopathic thrombocytopenic purpura (ITP) patients where surgery is contraindicated. Anti-CD20 rituximab, an immunosuppressant, is currently used off-label. This analysis compared the cost per responder for romiplostim versus rituximab in Spain. Read More

View Article and Full-Text PDF

Romiplostim as early treatment for refractory primary immune thrombocytopenia.

Int J Hematol 2013 Nov 26;98(5):520-4. Epub 2013 Sep 26.

Service de Médecine Interne et Maladies Infectieuses, Hôpital Haut-Lévêque, Avenue de Magellan, 33604, Pessac Cedex, France.

Romiplostim is a thrombopoietin-receptor agonist approved to treat chronic immune thrombocytopenia (ITP). We treated eight patients with acute or persistent primary ITP, severe clinical bleeding, and resistance to corticosteroids and/or intravenous immunoglobulins (IVIg). Romiplostim, initially administered at 2 or 3 μg/kg/week, was subsequently increased to achieve and maintain platelet-count responses and control bleeding. Read More

View Article and Full-Text PDF
November 2013

Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.

Br J Haematol 2013 Sep 6;162(5):693-701. Epub 2013 Jul 6.

Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.

Low doses of the humanized anti-CD20 monoclonal antibody, veltuzumab, were evaluated in 41 patients with immune thrombocytopenia (ITP), including 9 with ITP ≤1 year duration previously treated with steroids and/or immunoglobulins, and 32 with ITP >1 year and additional prior therapies. They received two doses of 80-320 mg veltuzumab 2 weeks apart, initially by intravenous (IV) infusion (N = 7), or later by subcutaneous (SC) injections (N = 34), with only one Grade 3 infusion reaction and no other safety issues. Thirty-eight response-assessable patients had 21 (55%) objective responses (platelet count ≥30 × 10(9) /l and ≥2 × baseline), including 11 (29%) complete responses (CRs) (platelet count ≥100 × 10(9) /l). Read More

View Article and Full-Text PDF
September 2013

Acute renal failure in a child with thrombocytopenic purpura caused by acute Epstein-Barr virus infection after treatment with anti-D immunoglobulin.

Pediatr Emerg Care 2013 Jun;29(6):748-50

Second Department of Pediatrics, Athens University, Greece.

Immune thrombocytopenia (ITP) in children is usually a benign, self-limiting disorder. An acute Epstein-Barr virus (EBV) infection usually causes atypical lymphocytosis and mild decrease in platelets. Severe thrombocytopenia is an extremely rare complication. Read More

View Article and Full-Text PDF

[Successful delivery following treatment with plasma exchange in a female patient with thrombotic thrombocytopenic purpura].

Rinsho Ketsueki 2012 Aug;53(8):770-3

Department of Hematology, Social Insurance Chukyo Hospital, Japan.

We report here on a case of a 27-year-old woman in her first pregnancy. She was diagnosed with idiopathic thrombocytopenic purpura (ITP) at the age of 14 years. At 36 weeks of gestation, she was admitted to our hospital due to thrombocytopenia. Read More

View Article and Full-Text PDF

A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin.

J Vet Emerg Crit Care (San Antonio) 2011 Oct;21(5):471-83

Department of Emergency and Critical Care, The Animal Medical Center, New York, NY 10065, USA.

Objective: To review and summarize the body of literature regarding human intravenous immunoglobulin (hIVIG) therapy in veterinary medicine. Mechanism of action, usage in human medicine, adverse effects of therapy, implications for veterinary use, and administration recommendations are discussed.

Data Sources: Current human and veterinary peer-reviewed medical literature including original research articles and scientific reviews. Read More

View Article and Full-Text PDF
October 2011